ArticleBMC bioinformatics2007
Reproducibility of microarray data: a further analysis of microarray quality control (MAQC) data.
Article in BMC bioinformatics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review of the Diagnostic and Clinical Utility of Salivary microRNAs in Traumatic Brain Injury (TBI).International journal of molecular sciences · 2022Pooled it
- Multi-Omics Analysis Identified Drug Repurposing Targets for Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2024Article
- Multi-omics data integration using ratio-based quantitative profiling with Quartet reference materials.Nature biotechnology · 2024Article
- Towards reproducible research in recurrent pregnancy loss immunology: Learning from cancer microenvironment deconvolution.Frontiers in immunology · 2023Article
- A simplified machine learning model utilizing platelet-related genes for predicting poor prognosis in sepsis.Frontiers in immunology · 2023Article
- Uniformly shaped harmonization combines human transcriptomic data from different platforms while retaining their biological properties and differential gene expression patterns.Frontiers in molecular biosciences · 2023Article
- Transcriptomic Harmonization as the Way for Suppressing Cross-Platform Bias and Batch Effect.Biomedicines · 2022Review
- Evaluation of connectivity map shows limited reproducibility in drug repositioning.Scientific reports · 2021Article
- Full pathogen characterisation: species identification including the detection of virulence factors and antibiotic resistance genes via multiplex DNA-assays.Scientific reports · 2021Article
- Identification of candidate repurposable drugs to combat COVID-19 using a signature-based approach.Scientific reports · 2021Article
- Curation of over 10 000 transcriptomic studies to enable data reuse.Database : the journal of biological databases and curation · 2021Article
- GEOlimma: differential expression analysis and feature selection using pre-existing microarray data.BMC bioinformatics · 2021Article
- Reanalysis and integration of public microarray datasets reveals novel host genes modulated in leprosy.Molecular genetics and genomics : MGG · 2020Article
- Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach.Physiological genomics · 2020Article
- Article
- Working Towards a Blood-Derived Gene Expression Biomarker Specific for Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2020Article
- Article
- Considerations for Strategic Use of High-Throughput Transcriptomics Chemical Screening Data in Regulatory Decisions.Current opinion in toxicology · 2019Article
- Small sample sizes in high-throughput miRNA screens: A common pitfall for the identification of miRNA biomarkers.Biomolecular detection and quantification · 2018Article
- Transcriptomics technologies.PLoS computational biology · 2017Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany researchers are concerned with the comparability and reliability of microarray gene expression data. Recent completion of the MicroArray Quality Control (MAQC) project provides a unique opportunity to assess reproducibility across multiple sites and the comparability across multiple platforms. The MAQC analysis presented for the conclusion of inter- and intra-platform comparability/reproducibility of microarray gene expression measurements is inadequate. We evaluate the reproducibility/comparability of the MAQC data for 12901 common genes in four titration samples generated from five high-density one-color microarray platforms and the TaqMan technology. We discuss some of the problems with the use of correlation coefficient as metric to evaluate the inter- and intra-platform reproducibility and the percent of overlapping genes (POG) as a measure for evaluation of a gene selection procedure by MAQC.
resultsA total of 293 arrays were used in the intra- and inter-platform analysis. A hierarchical cluster analysis shows distinct differences in the measured intensities among the five platforms. A number of genes show a small fold-change in one platform and a large fold-change in another platform, even though the correlations between platforms are high. An analysis of variance shows thirty percent of gene expressions of the samples show inconsistent patterns across the five platforms. We illustrated that POG does not reflect the accuracy of a selected gene list. A non-overlapping gene can be truly differentially expressed with a stringent cut, and an overlapping gene can be non-differentially expressed with non-stringent cutoff. In addition, POG is an unusable selection criterion. POG can increase or decrease irregularly as cutoff changes; there is no criterion to determine a cutoff so that POG is optimized.
conclusionUsing various statistical methods we demonstrate that there are differences in the intensities measured by different platforms and different sites within platform. Within each platform, the patterns of expression are generally consistent, but there is site-by-site variability. Evaluation of data analysis methods for use in regulatory decision should take no treatment effect into consideration, when there is no treatment effect, "a fold-change cutoff with a non-stringent p-value cutoff" could result in 100% false positive error selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.